LON:VRP - Verona Pharma plc (VRP.L) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 55
▲ +3 (5.77%)

This chart shows the closing price for VRP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Verona Pharma plc (VRP.L) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRP

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Verona Pharma plc (VRP.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 55.

This chart shows the closing price for VRP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Verona Pharma plc (VRP.L). This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/14/2020Shore CapitalReiterated RatingHold
4/30/2020Shore CapitalDowngradeHold
2/3/2020Shore CapitalReiterated RatingBuy
8/5/2019Shore CapitalReiterated RatingBuy
6/4/2019Shore CapitalReiterated RatingBuy
4/9/2019Shore CapitalReiterated RatingBuy
3/4/2019Shore CapitalReiterated RatingBuy
2/26/2019Shore CapitalReiterated RatingBuy
1/14/2019Shore CapitalReiterated RatingBuy
1/4/2019Jefferies Financial GroupReiterated RatingBuy
11/6/2018Shore CapitalReiterated RatingBuy
10/31/2018Shore CapitalReiterated RatingBuy
8/7/2018Jefferies Financial GroupReiterated RatingBuy
8/7/2018Shore CapitalReiterated RatingBuy
5/8/2018Shore CapitalLower Price TargetBuyGBX 173 ➝ GBX 160
4/11/2018Shore CapitalInitiated CoverageBuyGBX 173
4/6/2018Jefferies Financial GroupReiterated RatingBuy
3/21/2018N+1 SingerBoost Price TargetStrong-BuyGBX 327 ➝ GBX 348
3/2/2018N+1 SingerReiterated RatingStrong-Buy
11/27/2017N+1 SingerReiterated RatingBuyGBX 327
11/8/2017Jefferies Financial GroupReiterated RatingBuyGBX 250
11/7/2017N+1 SingerReiterated RatingBuy
6/27/2017N+1 SingerReiterated Ratingcorporate
6/9/2017Jefferies Financial GroupReiterated RatingBuyGBX 250
5/22/2017WedbushInitiated CoverageOutperformGBX 25
5/22/2017SunTrust BanksInitiated CoverageBuyGBX 26
5/22/2017Stifel NicolausInitiated CoverageBuyGBX 22
5/22/2017Jefferies Financial GroupInitiated CoverageBuyGBX 250
4/19/2017N+1 SingerReiterated RatingCorporate
4/4/2017N+1 SingerReiterated Ratingcorporate
3/22/2017N+1 SingerReiterated RatingCorporate
2/22/2017N+1 SingerReiterated RatingCorporate
1/18/2017N+1 SingerReiterated RatingCorporate
1/6/2017N+1 SingerReiterated RatingCorporate
9/26/2016N+1 SingerReiterated RatingCorporate
(Data available from 9/23/2016 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Verona Pharma plc (VRP.L) logo
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 55
Low: 50
High: 56

50 Day Range

MA: GBX 28.10
Low: 26.27
High: 55

52 Week Range

Now: GBX 55
Low: 28.60
High: 115

Volume

70,791 shs

Average Volume

150,610 shs

Market Capitalization

£228.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Verona Pharma plc (VRP.L)?

The following equities research analysts have issued reports on Verona Pharma plc (VRP.L) in the last year:
View the latest analyst ratings for VRP.

What is the current price target for Verona Pharma plc (VRP.L)?

0 Wall Street analysts have set twelve-month price targets for Verona Pharma plc (VRP.L) in the last year. has the lowest price target set, forecasting a price of £100,000 for Verona Pharma plc (VRP.L) in the next year.
View the latest price targets for VRP.

What is the current consensus analyst rating for Verona Pharma plc (VRP.L)?

Verona Pharma plc (VRP.L) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VRP.

What other companies compete with Verona Pharma plc (VRP.L)?

How do I contact Verona Pharma plc (VRP.L)'s investor relations team?

Verona Pharma plc (VRP.L)'s physical mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company's listed phone number is +44-20-32834200. The official website for Verona Pharma plc (VRP.L) is www.veronapharma.com.